# Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

> **NCT04419272** · PHASE4 · RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 226 (estimated)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Methylphenidate
- **OTHER:** Placebo
- **DRUG:** Methylphenidate

## Key facts

- **NCT ID:** NCT04419272
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-14
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 226 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04419272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04419272, "Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04419272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*